Scholars Central

Conference abstractPublished 5 Dec 2018

Development and validation of a liquid biopsy test for HPV associated oropharyngeal cancer

Authors: Sunil Kumar Bhishamjit S Chera, Colette Shen, Robert Amdur, Roi Dagan, Jared Weiss, Juneko Grilley-Olson, Adam Zanation, Trevor Hackman, Jeff Blumberg, Samip Patel, Brian Thorp, Mark Weissler, Nathan Sheets, William Mendenhall, Gaorav P Gupta

University of North Carolina School of Medicine, USA; Rex/UNC Hospital, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

There are two major risk factors for oropharyngeal cancer. It is well known that tobacco smoking and alcohol consumption causes oral cancer but there is an increasing prevalence of oropharyngeal cancer that is associated with human papillomavirus (HPV) infection. Disease control and survival are significantly better when HPV infection is involved. HPV status is routinely used for prognosis and is beginning to influence treatment decisions. An easily available biological sample and a sensitive method for HPV detection is a need to check HPV status before, during, and after completing therapy. We have designed and validated an ultrasensitive droplet digital PCR and TaqMan probe-based assay to detect and quantify HPV (subtypes 16, 18, 31, 33 and 35) in liquid biopsy samples. Plasma circulating tumor HPV16 DNA (ctHPV16DNA) was evaluated serially over time in patients who completed 6 weeks of de-intensified chemo-radiotherapy to analyze HPV status in our ongoing prospective phase II clinical trial. The HPV status was compared with the treatment response. Baseline plasma circulating tumor HPV-16 DNA (ctHPV16DNA) was detectable in 81 out of 102 patients in the study cohort (79%). Baseline ctHPV16DNA levels were highly variable and did not significantly correlate with any standard clinical factors including T stage, N stage, or smoking status. However, there was a good correlation between plasma ctHPV16DNA density and tumor HPV copies. ctHPV16DNA was cleared by week 6 of the treatment from the majority of the HPV16 positive patients. HPV variant strains were detected in many patients with undetectable baseline HPV16. We report ctHPV16DNA kinetics and disease control. Our data suggest plasma ctHPV16DNA profiles may be a useful biomarker of disease control. Undetectable ctHPV16DNA, low ctHPV16DNA, HPV variants, and delayed clearance kinetics may reflect worse disease prognosis compared to patients with high ctHPV16DNA that is rapidly cleared during treatment.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Drug Designing: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDrug Designing: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Sunil Kumar Bhishamjit S Chera”
  • BylineArticles whose byline prints “Colette Shen”
  • BylineArticles whose byline prints “Robert Amdur”
  • BylineArticles whose byline prints “Roi Dagan”
  • BylineArticles whose byline prints “Jared Weiss”
  • BylineArticles whose byline prints “Juneko Grilley-Olson”
  • BylineArticles whose byline prints “Adam Zanation”
  • BylineArticles whose byline prints “Trevor Hackman”